Liposarcoma clinical trials

Explore recruiting liposarcoma clinical trials.

Recruiting liposarcoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Liposarcoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin (BI 907828) treatment in patients with treatment-naïve or pre-treated advanced dedifferentiated liposarcoma

Belgium, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma

Netherlands, Belgium, Czechia, Portugal, Spain, Norway +6 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (SPEARHEAD 1 STUDY)

France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

PERELI - A phase 2, open label study of PEmigatinib and REtifanlimab in advanced dedifferentiated Liposarcoma

Sweden, Norway, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adult Participants With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas - (THE INVINCIBLE-3 TRIAL)

Spain, France, Poland, Germany, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA (BEXAR Study)

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Liposarcoma trials by city

Liposarcoma in Toronto Liposarcoma in Vancouver Liposarcoma in Montreal Liposarcoma in Calgary Liposarcoma in Edmonton Liposarcoma in Ottawa Liposarcoma in Winnipeg Liposarcoma in Quebec City Liposarcoma in Hamilton Liposarcoma in Kitchener Liposarcoma in London Liposarcoma in Halifax Liposarcoma in New York Liposarcoma in Los Angeles Liposarcoma in Chicago Liposarcoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease